NEW YORK, Nov. 12, 2024 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global Glaucoma Therapeutics Market is experiencing significant growth owing to the ...
Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development ...
SOUTH SAN FRANCISCO, Calif. & BRIDGEWATER, N.J., November 12, 2024--Cellares, the world’s first Integrated Development and ...
Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...
John Gustofson, MS, MBA appointed to the Board of Directors The appointment is in conjunction with Chugai Venture Fund joining syndicate with an investment that brings Hyku’s total seed financing to ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...
The global sore throat lozenges market is projected to be valued at USD 4.4 billion in 2024 and is expected to grow at a CAGR of 5.6%, reaching an estimated value of approximately USD 7.5 billion by ...
Hoffmann-La Roche Ltd, Sanofi-Aventis, Bristol-Myers Squibb Company, AbbVie, Inc., Novartis AG, GlaxoSmithKline PLC, Celgene Corporation, Johnson & Johnson Services, Inc., and Takeda Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback